TYROBP genetic variants in early-onset Alzheimer's disease

We aimed to identify new candidate genes potentially involved in early-onset Alzheimer's disease (EOAD). Exome sequencing was conducted on 45 EOAD patients with either a family history of Alzheimer's disease (AD, <65 years) or an extremely early age at the onset (≤55 years) followed by multiple variant filtering according to different modes of inheritance. We identified 29 candidate genes potentially involved in EOAD, of which the gene TYROBP, previously implicated in AD, was selected for genetic and functional follow-up. Using 3 patient cohorts, we observed rare coding TYROBP variants in 9 out of 1110 EOAD patients, whereas no such variants were detected in 1826 controls (p = 0.0001), suggesting that at least some rare TYROBP variants might contribute to EOAD risk. Overexpression of the p.D50_L51ins14 TYROBP mutant led to a profound reduction of TREM2 expression, a well-established risk factor for AD. This is the first study supporting a role for genetic variation in TYROBP in EOAD, with in vitro support for a functional effect of the p.D50_L51ins14 TYROBP mutation on TREM2 expression.

[1]  Toshiro K. Ohsumi,et al.  The Microglial Sensome Revealed by Direct RNA Sequencing , 2013, Nature Neuroscience.

[2]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[3]  Rosa Rademakers,et al.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? , 2012, Current opinion in neurology.

[4]  S. Leal,et al.  Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. , 2008, American journal of human genetics.

[5]  Huaxi Xu,et al.  DAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response* , 2015, The Journal of Biological Chemistry.

[6]  Erick R. Scott,et al.  Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease , 2013, Nature.

[7]  H. Neumann,et al.  Sequential Proteolytic Processing of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) Protein by Ectodomain Shedding and γ-Secretase-dependent Intramembranous Cleavage* , 2013, The Journal of Biological Chemistry.

[8]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[9]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[10]  M. Bullido,et al.  Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia , 2014, Neurobiology of Aging.

[11]  Irving E. Vega,et al.  Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration , 2012, Neuroreport.

[12]  M. Colonna,et al.  A Dap12-Mediated Pathway Regulates Expression of Cc Chemokine Receptor 7 and Maturation of Human Dendritic Cells , 2001, The Journal of experimental medicine.

[13]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[14]  Steven N. Hart,et al.  The Biological Reference Repository (BioR): a rapid and flexible system for genomics annotation , 2014, Bioinform..

[15]  Jing Ma,et al.  TYROBP in Alzheimer’s Disease , 2014, Molecular Neurobiology.

[16]  A. Fagan,et al.  Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status , 2016, Acta Neuropathologica.

[17]  D. Campion,et al.  TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[18]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[19]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[20]  A. Singleton,et al.  Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease , 2012, Neurobiology of Aging.

[21]  Dennis W Dickson,et al.  C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. , 2012, American journal of neurodegenerative disease.

[22]  A. Montpetit,et al.  Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons , 2015, European Journal of Human Genetics.

[23]  F. Borràs,et al.  Functional analysis of the CD300e receptor in human monocytes and myeloid dendritic cells , 2010, European journal of immunology.

[24]  R. Petersen,et al.  Mutations in the colony stimulating factor 1 receptor (CSF1R) cause hereditary diffuse leukoencephalopathy with spheroids , 2011, Nature Genetics.

[25]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[26]  Derek J Van Booven,et al.  GEnomes Management Application (GEM.app): A New Software Tool for Large‐Scale Collaborative Genome Analysis , 2013, Human mutation.

[27]  M. Daly,et al.  Variant TREM2 as risk factor for Alzheimer's disease. , 2013, The New England journal of medicine.

[28]  Margaret A. Pericak-Vance,et al.  Segregation of a rare TTC3 variant in an extended family with late-onset Alzheimer disease , 2016, Neurology: Genetics.

[29]  B Croisile,et al.  High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease , 2012, Molecular Psychiatry.

[30]  Leena Peltonen,et al.  Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts , 2000, Nature Genetics.

[31]  M. Jurkowska,et al.  Structure, expression pattern and biological activity of molecular complex TREM-2/DAP12. , 2013, Human immunology.

[32]  Manasi Malik,et al.  Genetics ignite focus on microglial inflammation in Alzheimer’s disease , 2015, Molecular Neurodegeneration.

[33]  K. Tomizawa,et al.  Amphiphysin I and regulation of synaptic vesicle endocytosis. , 2009, Acta medica Okayama.

[34]  A. Goate,et al.  Coding variants in TREM2 increase risk for Alzheimer's disease. , 2014, Human molecular genetics.

[35]  C. Cruchaga,et al.  TREM2 is associated with the risk of Alzheimer's disease in Spanish population , 2013, Neurobiology of Aging.